1 エグゼクティブ・サマリー
2 序文
2.1 概要
2.2 ステークホルダー
2.3 調査範囲
2.4 調査方法
2.4.1 データマイニング
2.4.2 データ分析
2.4.3 データの検証
2.4.4 リサーチアプローチ
2.5 リサーチソース
2.5.1 一次調査ソース
2.5.2 セカンダリーリサーチソース
2.5.3 前提条件
3 市場動向分析
3.1 はじめに
3.2 推進要因
3.3 抑制要因
3.4 機会
3.5 脅威
3.6 製品分析
3.7 アプリケーション分析
3.8 エンドユーザー分析
3.9 新興市場
3.10 Covid-19の影響
4 ポーターズファイブフォース分析
4.1 供給者の交渉力
4.2 買い手の交渉力
4.3 代替品の脅威
4.4 新規参入の脅威
4.5 競争上のライバル関係
5 タンパク質治療薬の世界市場（製品タイプ別
5.1 はじめに
5.2 モノクローナル抗体
5.3 インスリン
5.4 融合タンパク質
5.5 エリスロポエチン
5.6 インターフェロン
5.7 その他の製品タイプ
6 タンパク質治療薬の世界市場、機能別
6.1 はじめに
6.2 代替療法
6.3 刺激療法
6.4 阻害療法
6.5 中和療法
7 タンパク質治療薬の世界市場、供給源別
7.1 導入
7.2 動物由来
7.3 微生物由来
7.4 植物由来
7.5 組換え由来
8 タンパク質治療薬の世界市場、投与経路別
8.1 導入
8.2 注射剤
8.2.1 皮下
8.2.2 静脈内
8.2.3 筋肉内
8.3 経口
8.4 経皮
8.5 吸入
9 タンパク質治療薬の世界市場、用途別
9.1 はじめに
9.2 がん領域
9.3 自己免疫疾患
9.4 感染症
9.5 代謝性疾患
9.6 循環器疾患
9.7 神経疾患
9.8 その他の用途
10 タンパク質治療薬の世界市場、エンドユーザー別
10.1 導入
10.2 病院
10.3 製薬会社
10.4 研究機関
10.5 バイオテクノロジー企業
10.6 その他のエンドユーザー
11 タンパク質治療薬の世界市場、地域別
11.1 はじめに
11.2 北米
11.2.1 アメリカ
11.2.2 カナダ
11.2.3 メキシコ
11.3 ヨーロッパ
11.3.1 ドイツ
11.3.2 イギリス
11.3.3 イタリア
11.3.4 フランス
11.3.5 スペイン
11.3.6 その他のヨーロッパ
11.4 アジア太平洋
11.4.1 日本
11.4.2 中国
11.4.3 インド
11.4.4 オーストラリア
11.4.5 ニュージーランド
11.4.6 韓国
11.4.7 その他のアジア太平洋地域
11.5 南米
11.5.1 アルゼンチン
11.5.2 ブラジル
11.5.3 チリ
11.5.4 その他の南米地域
11.6 中東・アフリカ
11.6.1 サウジアラビア
11.6.2 アラブ首長国連邦
11.6.3 カタール
11.6.4 南アフリカ
11.6.5 その他の中東・アフリカ地域
12 主要開発
12.1 契約、パートナーシップ、提携、合弁事業
12.2 買収と合併
12.3 新製品上市
12.4 拡張
12.5 その他の主要戦略
13 企業プロフィール
Eli Lilly and Company
Merck & Co. Inc.
Novo Nordisk A/S
Amgen Inc.
Pfizer Inc.
Baxter International Inc.
Abbott Laboratories
Abbvie Inc.
Johnson & Johnson
Sanofi
Takeda Pharmaceutical Company Limited
Bayer AG
Generex Biotechnology Corp.
Teva Pharmaceutical Industries Ltd
AstraZeneca
BioNtech
Ractigen Therapeutics.
表一覧
表1 タンパク質治療薬の世界市場展望：地域別（2022-2030年） ($MN)
表2 タンパク質治療薬の世界市場展望：製品タイプ別（2022-2030年） ($MN)
表3 タンパク質治療薬の世界市場展望：モノクローナル抗体別 (2022-2030) ($MN)
表4 タンパク質治療薬の世界市場展望：インスリン別 (2022-2030) ($MN)
表5 タンパク質治療薬の世界市場展望：融合タンパク質別 (2022-2030) ($MN)
表6 タンパク質治療薬の世界市場展望：エリスロポエチン別 (2022-2030) ($MN)
表7 タンパク質治療薬の世界市場展望：インターフェロン別 (2022-2030) ($MN)
表8 タンパク質治療薬の世界市場展望：その他の製品タイプ別 (2022-2030) ($MN)
表9 タンパク質治療薬の世界市場展望：機能別（2022-2030年） ($MN)
表10 タンパク質治療薬の世界市場展望：置換療法別（2022-2030年） ($MN)
表11 タンパク質治療薬の世界市場展望：刺激療法別 (2022-2030) ($MN)
表12 タンパク質治療薬の世界市場展望：阻害療法別 (2022-2030) ($MN)
表13 タンパク質治療薬の世界市場展望：中和療法別（2022-2030年） ($MN)
表14 タンパク質治療薬の世界市場展望：供給源別 (2022-2030) ($MN)
表15 タンパク質治療薬の世界市場展望：動物由来（2022-2030年）別 ($MN)
表16 タンパク質治療薬の世界市場展望：微生物由来別 (2022-2030) ($MN)
表17 タンパク質治療薬の世界市場展望：植物由来別 (2022-2030) ($MN)
表18 タンパク質治療薬の世界市場展望：遺伝子組換え源別 (2022-2030) ($MN)
表19 タンパク質治療薬の世界市場展望：投与経路別 (2022-2030) ($MN)
表20 タンパク質治療薬の世界市場展望：注射剤別 (2022-2030) ($MN)
表21 タンパク質治療薬の世界市場展望：皮下投与（2022-2030年）別 ($MN)
表22 タンパク質治療薬の世界市場展望：静脈内投与（2022-2030年）別 ($MN)
表23 タンパク質治療薬の世界市場展望：筋肉内投与（2022-2030年）別 ($MN)
表24 タンパク質治療薬の世界市場展望：経口剤別 (2022-2030) ($MN)
表25 タンパク質治療薬の世界市場展望：経皮別 (2022-2030) ($MN)
表26 タンパク質治療薬の世界市場展望：吸入別 (2022-2030) ($MN)
表27 タンパク質治療薬の世界市場展望：用途別 (2022-2030) ($MN)
表28 タンパク質治療薬の世界市場展望：腫瘍学別 (2022-2030) ($MN)
表29 タンパク質治療薬の世界市場展望：自己免疫疾患別 (2022-2030) ($MN)
表30 タンパク質治療薬の世界市場展望：感染症別 (2022-2030) ($MN)
表31 タンパク質治療薬の世界市場展望：代謝疾患別 (2022-2030) ($MN)
表32 タンパク質治療薬の世界市場展望：心血管疾患別 (2022-2030) ($MN)
表33 タンパク質治療薬の世界市場展望：神経疾患別 (2022-2030) ($MN)
表34 タンパク質治療薬の世界市場展望：その他の用途別 (2022-2030) ($MN)
表35 タンパク質治療薬の世界市場展望：エンドユーザー別 (2022-2030) ($MN)
表36 タンパク質治療薬の世界市場展望：病院別 (2022-2030) ($MN)
表37 タンパク質治療薬の世界市場展望：製薬会社別 (2022-2030) ($MN)
表38 タンパク質治療薬の世界市場展望：研究機関別（2022-2030年） ($MN)
表39 タンパク質治療薬の世界市場展望：バイオテクノロジー企業別（2022-2030年） ($MN)
表40 タンパク質治療薬の世界市場展望：その他のエンドユーザー別 (2022-2030) ($MN)
注：北米、ヨーロッパ、APAC、南米、中東・アフリカ地域の表も上記と同様に表記しています。
According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths ly. Protein therapeutics are often used to treat these conditions, driving growth in the market.
Market Dynamics:
Driver:
Increasing prevalence of chronic diseases
The rising prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, is significantly driving growth in the market. As these conditions become more common, the demand for targeted and effective treatment options increases. Protein therapeutics, known for their precision and ability to modify complex biological pathways, are increasingly favored for managing these diseases. This trend is further supported by advancements in biotechnology and personalized medicine, leading to innovative therapies.
Restraint:
Biosimilarity and bioequivalence concerns
Concerns regarding biosimilarity and bioequivalence significantly hinder the market. Uncertainties about whether biosimilars can match the efficacy and safety of reference products lead to reluctance among healthcare providers and patients to embrace these alternatives. Additionally, the complexity of regulatory requirements may delay the entry of cost-effective biosimilars, ultimately limiting patient access to more affordable treatments for chronic conditions and perpetuating high healthcare costs.
Opportunity:
Growing research and development investments
Growing investments in research and development are fueling advancements in the market, driving innovation and expanding treatment options. Pharmaceutical companies are increasingly allocating resources to explore novel protein-based therapies, targeting complex diseases such as cancer, autoimmune disorders, and rare genetic conditions. This surge in funding supports cutting-edge technologies like gene editing and protein engineering, enhancing the specificity and efficacy of therapeutic candidates.
Threat:
High development and manufacturing costs
High development and manufacturing costs are significant challenges in the market, often limiting accessibility and affordability. The complex processes required for designing, producing, and purifying protein-based therapies demand substantial financial investment and specialized expertise. These financial barriers may deter smaller companies from entering the market and can lead to higher prices for patients and healthcare systems, ultimately impacting the overall availability of innovative treatment options.
Covid-19 Impact:
The COVID-19 pandemic had a profound impact on the protein therapeutics market, accelerating the development of novel treatments and vaccines. Increased funding and collaboration among researchers and pharmaceutical companies led to rapid advancements in protein-based therapies, particularly in addressing viral infections and immune responses. However, the pandemic also disrupted supply chains and clinical trials, delaying some therapeutic developments.
The fusion proteins segment is projected to be the largest during the forecast period
The fusion proteins segment is projected to account for the largest market share during the projection period. These engineered proteins can improve targeting mechanisms, extend half-life, and modulate immune responses, making them valuable in treating various diseases, including cancer and autoimmune disorders. Advances in biotechnology have facilitated the development of novel fusion proteins, leading to innovative therapies that can outperform traditional treatments.
The cardiovascular diseases segment is expected to have the highest CAGR during the forecast period
The cardiovascular diseases segment is expected to have the highest CAGR during the extrapolated period. Innovative protein-based therapies, such as monoclonal antibodies and peptides, are being developed to target specific pathways involved in heart disease, hypertension, and cholesterol management. As research advances, the growing understanding of the molecular mechanisms underlying CVDs is expected to drive the development of more effective protein therapeutics, improving patient outcomes.
Region with largest share:
North America region is projected to account for the largest market share during the forecast period. The region benefits from significant investments in healthcare innovation and a favorable regulatory environment that accelerates the approval of new therapies. With a high prevalence of chronic diseases and increasing demand for targeted treatments, it is home to numerous pharmaceutical companies and research institutions pioneering advancements in protein-based therapies, ultimately enhancing patient care and expanding market growth.
Region with highest CAGR:
Asia Pacific is expected to register the highest growth rate over the forecast period driven by increasing incidence of chronic diseases, such as cancer, diabetes, and autoimmune disorders. Governments and private entities in many countries are investing more in healthcare infrastructure and access, which has created opportunities for the market. The region has witnessed significant advancements in biotechnology, enabling the development and production of complex protein therapeutics.
Key players in the market
Some of the key players in Protein Therapeutics market include Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, Amgen Inc., Pfizer Inc., Baxter International Inc., Abbott Laboratories, Abbvie Inc., Johnson & Johnson, Sanofi, Takeda Pharmaceutical Company Limited, Bayer AG, Generex Biotechnology Corp., Teva Pharmaceutical Industries Ltd, AstraZeneca, BioNtech and Ractigen Therapeutics.
Key Developments:
In February 2024, BioNtech, a next-generation immunotherapy company, and Autolus, a clinical-stage biopharmaceutical company, announced the strategic collaboration for CAR-T Cell Therapy.
In January 2024, Ractigen Therapeutics, a leading clinical-stage pharmaceutical industry leader in charge of small activated RNA therapeutics, announced a strategic partnership with Utrecht University-affiliated University Medical Center. The collaboration strengthens the saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Product Types Covered:
• Monoclonal Antibodies
• Insulin
• Fusion Proteins
• Erythropoietin
• Interferon
• Other Product Types
Functions Covered:
• Replacement Therapy
• Stimulation Therapy
• Inhibition Therapy
• Neutralization Therapy
Sources Covered:
• Animal-Derived
• Microbial-Derived
• Plant-Derived
• Recombinant Sources
Route of Administrations Covered:
• Injectable
• Oral
• Transdermal
• Inhalation
Applications Covered:
• Oncology
• Autoimmune Disorders
• Infectious Diseases
• Metabolic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Other Applications
End Users Covered:
• Hospitals
• Pharmaceutical Companies
• Research Institutions
• Biotechnology Firms
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Protein Therapeutics Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.3 Insulin
5.4 Fusion Proteins
5.5 Erythropoietin
5.6 Interferon
5.7 Other Product Types
6 Global Protein Therapeutics Market, By Function
6.1 Introduction
6.2 Replacement Therapy
6.3 Stimulation Therapy
6.4 Inhibition Therapy
6.5 Neutralization Therapy
7 Global Protein Therapeutics Market, By Source
7.1 Introduction
7.2 Animal-Derived
7.3 Microbial-Derived
7.4 Plant-Derived
7.5 Recombinant Sources
8 Global Protein Therapeutics Market, By Route of Administration
8.1 Introduction
8.2 Injectable
8.2.1 Subcutaneous
8.2.2 Intravenous
8.2.3 Intramuscular
8.3 Oral
8.4 Transdermal
8.5 Inhalation
9 Global Protein Therapeutics Market, By Application
9.1 Introduction
9.2 Oncology
9.3 Autoimmune Disorders
9.4 Infectious Diseases
9.5 Metabolic Disorders
9.6 Cardiovascular Diseases
9.7 Neurological Disorders
9.8 Other Applications
10 Global Protein Therapeutics Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Pharmaceutical Companies
10.4 Research Institutions
10.5 Biotechnology Firms
10.6 Other End Users
11 Global Protein Therapeutics Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Eli Lilly and Company
13.2 Merck & Co. Inc.
13.3 Novo Nordisk A/S
13.4 Amgen Inc.
13.5 Pfizer Inc.
13.6 Baxter International Inc.
13.7 Abbott Laboratories
13.8 Abbvie Inc.
13.9 Johnson & Johnson
13.10 Sanofi
13.11 Takeda Pharmaceutical Company Limited
13.12 Bayer AG
13.13 Generex Biotechnology Corp.
13.14 Teva Pharmaceutical Industries Ltd
13.15 AstraZeneca
13.16 BioNtech
13.17 Ractigen Therapeutics
List of Tables
Table 1 Global Protein Therapeutics Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Protein Therapeutics Market Outlook, By Product Type (2022-2030) ($MN)
Table 3 Global Protein Therapeutics Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
Table 4 Global Protein Therapeutics Market Outlook, By Insulin (2022-2030) ($MN)
Table 5 Global Protein Therapeutics Market Outlook, By Fusion Proteins (2022-2030) ($MN)
Table 6 Global Protein Therapeutics Market Outlook, By Erythropoietin (2022-2030) ($MN)
Table 7 Global Protein Therapeutics Market Outlook, By Interferon (2022-2030) ($MN)
Table 8 Global Protein Therapeutics Market Outlook, By Other Product Types (2022-2030) ($MN)
Table 9 Global Protein Therapeutics Market Outlook, By Function (2022-2030) ($MN)
Table 10 Global Protein Therapeutics Market Outlook, By Replacement Therapy (2022-2030) ($MN)
Table 11 Global Protein Therapeutics Market Outlook, By Stimulation Therapy (2022-2030) ($MN)
Table 12 Global Protein Therapeutics Market Outlook, By Inhibition Therapy (2022-2030) ($MN)
Table 13 Global Protein Therapeutics Market Outlook, By Neutralization Therapy (2022-2030) ($MN)
Table 14 Global Protein Therapeutics Market Outlook, By Source (2022-2030) ($MN)
Table 15 Global Protein Therapeutics Market Outlook, By Animal-Derived (2022-2030) ($MN)
Table 16 Global Protein Therapeutics Market Outlook, By Microbial-Derived (2022-2030) ($MN)
Table 17 Global Protein Therapeutics Market Outlook, By Plant-Derived (2022-2030) ($MN)
Table 18 Global Protein Therapeutics Market Outlook, By Recombinant Sources (2022-2030) ($MN)
Table 19 Global Protein Therapeutics Market Outlook, By Route of Administration (2022-2030) ($MN)
Table 20 Global Protein Therapeutics Market Outlook, By Injectable (2022-2030) ($MN)
Table 21 Global Protein Therapeutics Market Outlook, By Subcutaneous (2022-2030) ($MN)
Table 22 Global Protein Therapeutics Market Outlook, By Intravenous (2022-2030) ($MN)
Table 23 Global Protein Therapeutics Market Outlook, By Intramuscular (2022-2030) ($MN)
Table 24 Global Protein Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
Table 25 Global Protein Therapeutics Market Outlook, By Transdermal (2022-2030) ($MN)
Table 26 Global Protein Therapeutics Market Outlook, By Inhalation (2022-2030) ($MN)
Table 27 Global Protein Therapeutics Market Outlook, By Application (2022-2030) ($MN)
Table 28 Global Protein Therapeutics Market Outlook, By Oncology (2022-2030) ($MN)
Table 29 Global Protein Therapeutics Market Outlook, By Autoimmune Disorders (2022-2030) ($MN)
Table 30 Global Protein Therapeutics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
Table 31 Global Protein Therapeutics Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
Table 32 Global Protein Therapeutics Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
Table 33 Global Protein Therapeutics Market Outlook, By Neurological Disorders (2022-2030) ($MN)
Table 34 Global Protein Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
Table 35 Global Protein Therapeutics Market Outlook, By End User (2022-2030) ($MN)
Table 36 Global Protein Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
Table 37 Global Protein Therapeutics Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
Table 38 Global Protein Therapeutics Market Outlook, By Research Institutions (2022-2030) ($MN)
Table 39 Global Protein Therapeutics Market Outlook, By Biotechnology Firms (2022-2030) ($MN)
Table 40 Global Protein Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
